| Peer-Reviewed

Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer

Received: 21 July 2023     Accepted: 7 August 2023     Published: 17 August 2023
Views:       Downloads:
Abstract

Objective: To analyze the related factors of venous thromboembolism in patients with ovarian cancer. Methods: A total of 86 patients with ovarian cancer complicated with VTE who were treated in a hospital from January 2021 to December 2022 were selected. The medical records of the patients were collected. The revised Caprini risk assessment scale (version 2013) was used to evaluate the risk level of VTE in patients with ovarian cancer, and the risk factors of VTE in patients with ovarian cancer were analyzed. Results: According to the revised Caprini risk assessment scale, 86 patients were scored, including 23 cases (26.74%) of high risk and 62 cases (72.09%) of extremely high risk. Among 86 patients, 77 cases (89.53%) were epithelial cancer, 75 cases (87.21%) were poorly differentiated cancer, 71 cases (82.56%) were International Federation of Gynecology and Obstetrics (FIGO) stage III-IV, and 28 cases (32.56%) were complicated with ascites. Thrombosis occurred before neoadjuvant chemotherapy in 9 cases (10.47%), during neoadjuvant chemotherapy in 5 cases (5.81%), before surgery in 21 cases (24.42%), during surgery in 1 case (jugular vein thrombosis), and after surgery in 50 cases (58.14%). VTE occurred in 26 patients (30.26%) with central venous catheter implantation and 22 patients (25.58%) with lymph node metastasis. Conclusions: According to the modified Caprini risk assessment scale, high risk and very high risk ovarian cancer patients are at high risk of VTE. The modified Caprini risk assessment scale is helpful for clinical early identification of patients with high risk of VTE. Tumor histological type, tumor grade, tumor staging and surgical treatment are related to the occurrence of VTE in patients with ovarian cancer.

Published in Journal of Cancer Treatment and Research (Volume 11, Issue 2)
DOI 10.11648/j.jctr.20231102.12
Page(s) 17-22
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Ovarian Cancer, Venous Thromboembolism, Risk Factors, Tumor Histological Type, Tumor Grade, Tumor Staging

References
[1] Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9; 371: m3773. doi: 10.1136/bmj.m3773. PMID: 33168565.
[2] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May; 71 (3): 209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
[3] Tang Ziying, Deng Minggang, Yu Chuanhua, Liu Qing. Current status and trend analysis of disease burden of ovarian cancer in China [J]. International Journal of Obstetrics and Gynecology, 2012, 49 (02): 222-227.
[4] Xu Z, Becerra AZ, Justiniano CF, Aquina CT, Fleming FJ, Boscoe FP, Schymura MJ, Sinno AK, Chaoul J, Morrow GR, Minasian L, Temkin SM. Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer. J Surg Res. 2020 Feb; 246: 34-41. doi: 10.1016/j.jss.2019.08.027. Epub 2019 Sep 24. PMID: 31561176; PMCID: PMC6917987.
[5] Lei HK, Li XS, Long B, et al. Analysis of clinical characteristics of patients with malignant tumors complicated with venous thromboembolism [J]. Cancer Prevention and Treatment Research, 2020, 47 (4): 256-261.
[6] Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021 Apr 20; 3 (2): 173-190. The doi: 10.1016 / j.j. Accao 2021.03.001. PMID: 34396323; PMCID: PMC8352228.
[7] Wang Jiaxi, Yu Hao, Zhang Shiqian. Expert consensus on the prevention of perioperative venous thromboembolism in patients with gynecological cancer (2022 edition) [J]. Chin J Cancer Prevention and Treatment, 2021, 29 (10): 687-694.
[8] Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013 Apr; 49 (6): 1404-13. Doi: 10.1016 / j. jca. 2012.10.021. Epub 2012 Nov 9. PMID: 23146958.
[9] Zhong XX. Application of air pressure therapeutic apparatus combined with comprehensive nursing in patients with ovarian cancer after surgery [J]. Medical Equipment, 2023, 36 (12): 121-124.
[10] Kumar A, Hurtt CC, Cliby WA, Martin JR, Weaver AL, McGree ME, Langstraat CL, Bakkum-Gamez JN. Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses. Gynecol Oncol. 2017 Dec; 147 (3): 514-520. doi: 10.1016/j.ygyno.2017.09.020. Epub 2017 Sep 22. PMID: 28947173.
[11] Peng Deqing, Lin Yan. Application progress of Caprini risk assessment model in predicting venous thromboembolism [J]. General Nursing, 2023, 21 (09): 1186-1190.
[12] LouY Y, Shen Y, et al. Effectiveness of Caprini risk assessment model in predicting the risk of deep venous thrombosis in patients undergoing gynecological malignant tumor surgery [J]. Journal of Southeast University (Medical Edition), 2017, 36 (03): 333-337.
[13] Wu Bei, Chen Guoping, Gu Jianping. Chin J Interventional Radiology, 2019, 7 (04): 322-329. (in Chinese).
[14] Li Rong, Huang Xiyue, Du Dan. Clinical characteristics of gynecological cancer patients complicated with venous thromboembolism [J]. Chinese Maternal and Child Health Research, 2017, 28 (12): 1719-1721.
[15] Ebina Y, Uchiyama M, Imafuku H, Suzuki K, Miyahara Y, Yamada H. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine (Baltimore). 2018 Jun; 97 (23): e11009. Doi: 10.1097 / MD. 0000000000011009. PMID: 29879062; PMCID: PMC5999475.
[16] Ma Li, Jin Yunfeng, Cao Yurong, Xue Wei-hong, Li Hui. Analysis of main risk factors of venous thromboembolism in gynecological perioperative period [J]. Journal of Applied Gynecological Endocrinology, 2020, 7 (23): 42-43.
[17] Wang Hong-xiang, Wang Tian-xiao, Yang Chun-hua, BI Ying-Yue, Xia Shan-shan. Value of systematic nursing combined with pneumatic therapy in preventing deep vein thrombosis of lower limbs in patients with multiple fractures [J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 31 (22): 3179-3182.
[18] Gan Hexia, Zhang Xiuping, Li Fang, Su Zhimin, Li Zhiyong. Risk factors of venous thrombosis in hospitalized patients with malignant tumors [J]. Chinese and Foreign Med, 2021, 40 (29): 85-88.
[19] Li Chaoming, Yang Mingyu, Hu Lin, Yin Tao. Influencing factors of venous thromboembolism in hospitalized patients with gynecological malignant tumors [J]. China Medical Engineering, 2019, 27 (02): 30-35.
[20] Gan Ling, Liu Shanjun, Xiao Xia, Yin Jiabao. [23] Liu S, Liu S, Xiao S, Yin J, et al. Venous stasis index to evaluate the risk of deep venous thrombosis of lower extremity after gynecological malignant tumor resection [J]. Chinese Journal of Medical Imaging, 2019, 29 (06): 1031-1034.
[21] Lv Shenglan. Analysis of risk factors for venous thromboembolism after gynecological malignant tumor surgery [D]. Tutor: Yang Jishi. Bengbu Medical College, 2015.
[22] Vahid Dastjerdi M, Ahmari S, Alipour S, Tehranian A. The comparison of plasma D-dimer levels in benign and malignant tumors of cervix, ovary and uterus. Int J Hematol Oncol Stem Cell Res. 2015 Jul 1; 9 (3): 107-11. PMID: 26261694; PMCID: PMC4529676.
[23] Wu Xuefeng, Li Xiaoou, Zhang Xiaowei. [26] WU XF, LI XW, ZHANG XW. Association between plasma D-dimer level and venous thromboembolism in patients with ovarian cancer [J]. Chin J Lab Diagnostics, 2016, 20 (10): 1718-1720.
[24] Tasaka N, Minaguchi T, Hosokawa Y, Takao W, Itagaki H, Nishida K, Akiyama A, Shikama A, Ochi H, Satoh T. Prevalence of venous thromboembolism at pretreatment screening and associated risk factors in 2086 patients with gynecological cancer. J Obstet Gynaecol Res. 2020 May; 46 (5): 765-773. doi: 10.1111/ jog.14233.Epub 2020 Mar 8.PMID: 32147891.
[25] Cronin M, Dengler N, Krauss ES, Segal A, Wei N, Daly M, Mota F, Caprini JA. Completion of the Updated Caprini Risk Assessment Model (2013 Version). Clin Appl Thromb Hemost. 2019 Jan-Dec; 76029619838052. The rest doi: 10.1177/1076029619838052. PMID: 30939900. PMCID: PMC6714938.
[26] Debbie Jiang MD, Alfred Ian Lee MD. Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treat Res. 2019; 179: 87-101. doi: 10.1007/978-3-030-20315-3_6.PMID: 31317482.
[27] Giustozzi M, Curcio A, Weijs B, Field TS, Sudikas S, Katholing A, Wallenhorst C, Weitz JI, Martinez C, Cohen AT. Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. Thromb Haemost. 2020 May; 120 (5): 847-856. doi: 10.1055/ s-0040-1709527.Epub 2020 May 5. PMID: 32369855.
[28] Tang Qin, Wang Ping. Clinical analysis of venous thromboembolism after gynecological surgery [J]. J Practical Ob & Gyn, 2020, 36 (01): 67-71.
[29] Chaoyi Cui, Rong Zhang, Jumin Song, Zhidang Wang, Chengwen Wu, Minyi Yin, Xiaobing Liu, Xinwu Lu, Xintian Huang. A multi-center clinical epidemiological study of symptomatic venous thromboembolism in patients after abdominal surgery [J]. Chin J Practical Surgery, 2020, 40 (05): 547-550+556.
[30] Wang Guiyun, Li Man, Wang Haibo. Clinical characteristics and related factors of venous thrombosis after gynecological surgery [J]. Trauma & Critical Care Medicine, 2019, 7 (01): 49-51.
[31] Chen Ying, Zhang Guangxia, Dong Xiuyan. Analysis of risk factors and nursing countermeasures of lower extremity deep venous thrombosis after gynecological malignant tumor surgery [J]. Journal of Qilu Nursing, 2020, 26 (18): 91-94.
Cite This Article
  • APA Style

    Liyang Hu, Lingling Lin, Zhongqiu Lu. (2023). Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer. Journal of Cancer Treatment and Research, 11(2), 17-22. https://doi.org/10.11648/j.jctr.20231102.12

    Copy | Download

    ACS Style

    Liyang Hu; Lingling Lin; Zhongqiu Lu. Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer. J. Cancer Treat. Res. 2023, 11(2), 17-22. doi: 10.11648/j.jctr.20231102.12

    Copy | Download

    AMA Style

    Liyang Hu, Lingling Lin, Zhongqiu Lu. Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer. J Cancer Treat Res. 2023;11(2):17-22. doi: 10.11648/j.jctr.20231102.12

    Copy | Download

  • @article{10.11648/j.jctr.20231102.12,
      author = {Liyang Hu and Lingling Lin and Zhongqiu Lu},
      title = {Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer},
      journal = {Journal of Cancer Treatment and Research},
      volume = {11},
      number = {2},
      pages = {17-22},
      doi = {10.11648/j.jctr.20231102.12},
      url = {https://doi.org/10.11648/j.jctr.20231102.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20231102.12},
      abstract = {Objective: To analyze the related factors of venous thromboembolism in patients with ovarian cancer. Methods: A total of 86 patients with ovarian cancer complicated with VTE who were treated in a hospital from January 2021 to December 2022 were selected. The medical records of the patients were collected. The revised Caprini risk assessment scale (version 2013) was used to evaluate the risk level of VTE in patients with ovarian cancer, and the risk factors of VTE in patients with ovarian cancer were analyzed. Results: According to the revised Caprini risk assessment scale, 86 patients were scored, including 23 cases (26.74%) of high risk and 62 cases (72.09%) of extremely high risk. Among 86 patients, 77 cases (89.53%) were epithelial cancer, 75 cases (87.21%) were poorly differentiated cancer, 71 cases (82.56%) were International Federation of Gynecology and Obstetrics (FIGO) stage III-IV, and 28 cases (32.56%) were complicated with ascites. Thrombosis occurred before neoadjuvant chemotherapy in 9 cases (10.47%), during neoadjuvant chemotherapy in 5 cases (5.81%), before surgery in 21 cases (24.42%), during surgery in 1 case (jugular vein thrombosis), and after surgery in 50 cases (58.14%). VTE occurred in 26 patients (30.26%) with central venous catheter implantation and 22 patients (25.58%) with lymph node metastasis. Conclusions: According to the modified Caprini risk assessment scale, high risk and very high risk ovarian cancer patients are at high risk of VTE. The modified Caprini risk assessment scale is helpful for clinical early identification of patients with high risk of VTE. Tumor histological type, tumor grade, tumor staging and surgical treatment are related to the occurrence of VTE in patients with ovarian cancer.},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Analysis of Related Factors of Venous Thromboembolism in Patients with Ovarian Cancer
    AU  - Liyang Hu
    AU  - Lingling Lin
    AU  - Zhongqiu Lu
    Y1  - 2023/08/17
    PY  - 2023
    N1  - https://doi.org/10.11648/j.jctr.20231102.12
    DO  - 10.11648/j.jctr.20231102.12
    T2  - Journal of Cancer Treatment and Research
    JF  - Journal of Cancer Treatment and Research
    JO  - Journal of Cancer Treatment and Research
    SP  - 17
    EP  - 22
    PB  - Science Publishing Group
    SN  - 2376-7790
    UR  - https://doi.org/10.11648/j.jctr.20231102.12
    AB  - Objective: To analyze the related factors of venous thromboembolism in patients with ovarian cancer. Methods: A total of 86 patients with ovarian cancer complicated with VTE who were treated in a hospital from January 2021 to December 2022 were selected. The medical records of the patients were collected. The revised Caprini risk assessment scale (version 2013) was used to evaluate the risk level of VTE in patients with ovarian cancer, and the risk factors of VTE in patients with ovarian cancer were analyzed. Results: According to the revised Caprini risk assessment scale, 86 patients were scored, including 23 cases (26.74%) of high risk and 62 cases (72.09%) of extremely high risk. Among 86 patients, 77 cases (89.53%) were epithelial cancer, 75 cases (87.21%) were poorly differentiated cancer, 71 cases (82.56%) were International Federation of Gynecology and Obstetrics (FIGO) stage III-IV, and 28 cases (32.56%) were complicated with ascites. Thrombosis occurred before neoadjuvant chemotherapy in 9 cases (10.47%), during neoadjuvant chemotherapy in 5 cases (5.81%), before surgery in 21 cases (24.42%), during surgery in 1 case (jugular vein thrombosis), and after surgery in 50 cases (58.14%). VTE occurred in 26 patients (30.26%) with central venous catheter implantation and 22 patients (25.58%) with lymph node metastasis. Conclusions: According to the modified Caprini risk assessment scale, high risk and very high risk ovarian cancer patients are at high risk of VTE. The modified Caprini risk assessment scale is helpful for clinical early identification of patients with high risk of VTE. Tumor histological type, tumor grade, tumor staging and surgical treatment are related to the occurrence of VTE in patients with ovarian cancer.
    VL  - 11
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

  • Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

  • Department of Emergency, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

  • Sections